Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02479308 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Effect of ALKS 5461 on QT Intervals in Healthy Volunteers
A Phase 1 study, sponsored by Alkermes.
- Completed
- Registry status
- Phase 1
- Development phase
- 129
- Enrollment target
NCT02479308 is a Phase 1 study that has completed, run by Alkermes. The registered enrollment target is 129 participants.
The verdict
NCT02479308, a Phase 1 study, has completed, sponsored by Alkermes.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 129 participants
- Enrollment target
Study Summary
This study will evaluate the effects of ALKS 5461 on QT intervals in healthy volunteers as well as evaluate the safety and tolerability of ALKS 5461.
Interventions
- DRUG Placebo
- DRUG Moxifloxacin
- DRUG ALKS 5461
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2015-06 |
| Est. Completion | 2015-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02479308
The ClinicalTrials.gov registry entry for NCT02479308 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 129 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alkermes, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02479308 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02479308 about?
NCT02479308 is a clinical study titled "A Study to Evaluate the Effect of ALKS 5461 on QT Intervals in Healthy Volunteers". This study will evaluate the effects of ALKS 5461 on QT intervals in healthy volunteers as well as evaluate the safety and tolerability of ALKS 5461.
What is the current status of trial NCT02479308?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 129 participants. The study started on 2015-06. Estimated completion is 2015-10.
What interventions are being tested in trial NCT02479308?
The interventions under investigation include: Placebo (DRUG), Moxifloxacin (DRUG), ALKS 5461 (DRUG).
Who is sponsoring clinical trial NCT02479308?
This trial is sponsored by Alkermes, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.